Minimal residual disease is potential early outcome measure in myeloma
Minimal residual disease or MRD — defined as a…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Cell therapy anito-cel shows promise for hard-to-treat RRMM
Most people with relapsed or refractory multiple myeloma…
Carvykti delays myeloma symptom worsening, per Phase 3 trial data
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier…
New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to…
FDA to review combinations of Blenrep for multiple myeloma
The U.S. Food and Drug Administration (FDA) will review…
Survival better with Blenrep combo than Darzalex for R/R myeloma
A combination therapy using Blenrep (belantamab mafodotin) was more…
